Who’s Hired? Stenico Takes Lead At Sandoz Germany

While Stada Also Makes Three German Appointments

12 May 2020

Sandoz has named Peter Stenico as permanent country head for its German operations. At the same time, Stada has appointed a trio of executives to key roles in Germany, Hovione has announced a new COO, Hikma and Orion have seen board changes and Sanofi’s biosimilars head in China has left the position for a new role.

Sandoz has announced the appointment of Peter Stenico as country head for Germany, as well as spokesman of the Hexal board of directors. Taking on the role from the start of May, Stenico replaces Stephan Eder, who left the firm at the beginning of the year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance

24 Apr 2025

• By Dave Wallace

Aeon Biopharma has picked up Revance Therapeutics executive Rob Bancroft to serve as its new CEO as it continues to pursue a biosimilar version of Botox. Meanwhile, Coherus has lost its chief commercial officer, as Viatris, Sandoz and Medicines for Ireland have announced new appointments.

Samsung Bioepis Reevaluating Approach To Biosimilars

22 Apr 2025

• By Jessica Merrill

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.

Cardinal Looks Ahead To A New Decade For US Biosimilars

20 Apr 2025

• By Dave Wallace

In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.

Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs

01 Apr 2025

• By Dave Wallace

Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

01 May 2025

• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.